Oncolytics Biotech (ONCY) executive compensation, 2026 proxy

Jared Kelly, Chief Executive Officer, was paid $2.1M in 2025.

Filed
October 6, 2026
Annual meeting
November 19, 2026
Pay year
2025
Named executives
4
CEO total pay
$2.1M2025
Corporate achievement level
50%Determined 2025 incentive awards
Kelly maximum PSU value
$784,484At maximum performance
Kelly short-term incentive target
50%Of prorated base salary
Pisano incentive target
50%Of base salary
Look incentive target
40%Of base salary
Heineman incentive target
40%Of base salary

How Kelly was paid

$2.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Option awards84%All other compensation0%

Named executive officers

ExecutiveTotal
Jared KellyChief Executive Officer$2,108,512
Wayne PisanoFormer Interim CEO$433,141
Thomas C. HeinemanChief Medical Officer$1,197,342
Kirk LookChief Financial Officer$1,122,229

What changed and why

  • $2.1M$2,108,512 Jared Kelly’s 2025 total compensation included $1,780,836 in option awards and no bonus.
  • June 11, 2025 Jared Kelly became CEO and received inducement options and performance share units.
  • 50%50% The Compensation Committee’s 2025 corporate achievement level determined short-term incentive awards.
  • $784K$784,484 Jared Kelly’s performance-based stock awards had this maximum-performance grant-date value.
  • $1.2M$1,197,342 Thomas C. Heineman’s 2025 total compensation included $521,871 in option awards.
  • $433K$433,141 Wayne Pisano’s 2025 total compensation included $40,000 in director compensation.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.